New COVID-19 booster studied for vulnerable patients
NCT ID NCT06027229
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a Novavax COVID-19 booster vaccine in 21 people with weakened immune systems due to inflammatory bowel disease or organ transplants. The goal was to see if the booster improved antibody levels and immune protection against COVID-19. Participants had already received at least three prior COVID-19 vaccine doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Novavax COVID-19 Vaccine (NVX-CoV2373) booster targeting Omicron XBB.1.5
- What this could lead to
- If successful, this could show that a recombinant booster vaccine improves COVID-19 protection in people with weakened immune systems.
- What could go wrong
- This is a small, early-phase study with only 21 participants, so results may not apply to everyone. The booster may not produce a strong immune response in all immunosuppressed patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UW School of Medicine and Public Health
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a new drug shield lungs from COVID-19's worst damage?